Close

DNA-encoded mAb Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Synthetic DNA-encoded mAb (DMAb) technology is a novel approach for direct immunoglobulin (Ig) production and secretion of functional mAb in vivo, according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Therefore, the DMAb strategy produces mAb in vivo, which allows for analysis that may otherwise be difficult to develop due to undesirable biophysical and biochemical sequence liabilities. Compared with the traditional mAb, DMAb therapeutic technology can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology represents a novel technology for delivery and expression of a novel, simple, less frequent, cost-effective antibodies for therapeutics.

Creative Biolabs focuses on the development of multiple DMAb products that enable in vivo delivery of highly potent mAbs. With this technology, engineered and synthetic DMAb plasmids encoding IgG inserts were directly injected into the muscle and delivered intracellularly by electroporation, leading to in vivo expression and secretion of the encoded IgG.

Custom DMAb Design

Creative Biolabs provides a wide range of customized DMAb at a reasonable cost and fast turnaround time. Our experienced scientists are ready to solve difficult cloning projects, including large or toxic clones or clones with high GC content or highly repetitive sequences. Please contact us to provide details of your DMAb project, our team will contact you as soon as possible. If you wish to add any other modifications or conjugations to your DMAb, please contact us for more information.

customizing CAR and CAR cell products

Fig.1 Schematic of two-plasmid and single-plasmid antibody-encoding DNA cassettes for human IgG expression. (Flingai, 2016)

Reference

  1. Flingai, S. (2016). Engineered DNA-mediated antibody gene transfer for prophylaxis against infectious diseases (Doctoral dissertation, University of Pennsylvania).

Please browse the target below to find the right product for you.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.